Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) is now available.
Shandong Xinhua Pharmaceutical Company Limited announced that it has received a Drug Registration Certificate from China’s National Medical Products Administration for its domestically produced 80mg valsartan capsules, a prescription medicine used to treat mild to moderate primary hypertension. The approval confirms that the product meets national drug registration and quality standards and allows the company to proceed toward commercial production and sales once pharmaceutical production quality management requirements are fulfilled, potentially strengthening its cardiovascular portfolio and competitive position in China’s hypertension treatment market.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a China-based pharmaceutical manufacturer engaged in the development, production and sale of prescription drugs and other chemical pharmaceutical products, with its H shares listed in Hong Kong and A shares traded on the domestic market. The company focuses on expanding its portfolio of cardiovascular and other therapeutic medicines for the domestic Chinese market, operating under national regulatory frameworks for drug registration and quality management.
Average Trading Volume: 2,146,783
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.98B
For detailed information about 0719 stock, go to TipRanks’ Stock Analysis page.